Navigation Links
ARIUS sale approved by shareholders
Date:9/18/2008

TORONTO, Sept. 18 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that ARIUS Research Inc. shareholders and warrant holders approved the proposed plan of arrangement involving the Company and Roche.

At a special meeting held in Toronto on September 16, 2008, ARIUS shareholders and warrant holders approved the transaction, with 99.99% of Common Shareholders and Class F Warrant holders, voting as a class, and 100% of Class G Warrant holders, represented in person or by proxy, voting in favor of the transaction. The completion of the transaction will result in Common Shareholders receiving $2.44 per Common Share, holders of Class F Warrants receiving $1.44 per Class F Warrant, and holders of Class G Warrants receiving $1.78 per Class G Warrant. The transaction is subject to final Court approval on September 19, 2008, and is expected to close shortly after obtaining Court approval and upon the satisfaction of certain closing conditions.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at http://www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.

The TSX has not reviewed and does not accept responsibility for the

adequacy or accuracy of this statement.


'/>"/>
SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
2. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
3. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
4. ARIUS to present at Chinese Global Financial Forum
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
8. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
9. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/11/2017)... ... 11, 2017 , ... A new study published in Fertility ... fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort ... After comparing the results from the fresh and frozen transfer cohorts, the authors ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... -- International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... market and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase ... "The residential security market has experienced continued growth, ...
Breaking Biology Technology:
(Date:7/20/2017)... 2017 Delta (NYSE: DAL ) customers now can ... at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan ... Delta,s biometric boarding pass experience that ... now integrated into the boarding process to allow eligible Delta SkyMiles Members ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:5/16/2017)... May 16, 2017   Bridge Patient Portal ... and MD EMR Systems , an electronic ... for GE, have established a partnership to build ... and the GE Centricity™ products, including Centricity Practice ... These new integrations will allow healthcare ...
Breaking Biology News(10 mins):